During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents ...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...

Gilead’s CAR-T cancer therapy has been approved in the US for an aggressive form of blood cancer, indicating the company’s $12 billion acquisition on Kite Pharma could pay off. Priced at $ ...

Synopsis: In a case with implications for the litigious molecular diagnostics space and written description law, Chief Judge Connolly ...

Story Jan. 10 - Shoreline Biosciences: The cell therapy biotech plans to let go of an undisclosed number of employees tied to a project with Gilead Sciences’ Kite Pharma. Story Jan. 9 - IGM ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

For 2025, we are focusing on preferred shares due to their attractive yields and lower risk. Check out John and Jane's ...

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results ...

Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet ...

Western Australia is set to host one of the most exciting and forward-thinking events in the life sciences sector.

A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell/File Photo Former Republican Representative ...

After hours: March 20 at 6:04:50 PM EDT Loading Chart for KRG ...